Related Experiment Video
Updated: Dec 24, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)
Alessandro Russo1,2, Ana Rita Lopes1,3, Michael G McCusker1
1Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, 22 S Greene Street Rm. N9E08, Baltimore, MD, 21201, USA.
Purpose Of Review:
Over the last two decades, the identification of targetable oncogene drivers has revolutionized the therapeutic landscape of non-small cell lung cancer (NSCLC). The extraordinary progresses made in molecular biology prompted the identification of several rare molecularly defined subgroups. In this review, we will focus on the novel and emerging actionable oncogenic drivers in NSCLC.
Recent Findings:
Recently, novel oncogene drivers emerged as promising therapeutic targets besides the well-established EGFR mutations, and ALK/ROS1 rearrangements, considerably expanding the list of potential exploitable genetic aberrations. However, the therapeutic algorithm in these patients is far less defined. The identification of uncommon oncogene drivers is reshaping the diagnostic and therapeutic approach to NSCLC. The introduction of novel highly selective inhibitors is expanding the use of targeted therapies to rare and ultra-rare subsets of patients, further increasing the therapeutic armamentarium of advanced NSCLC.
Insights
Novel oncogenic drivers are transforming non-small cell lung cancer (NSCLC) treatment, offering new targeted therapies for rare patient subgroups. This expands treatment options beyond established mutations and rearrangements.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Targetable oncogene drivers have significantly advanced non-small cell lung cancer (NSCLC) therapy over the past 20 years.
- Molecular biology advancements have identified rare, molecularly defined subgroups within NSCLC.
Purpose of the Study:
- To review novel and emerging actionable oncogenic drivers in NSCLC.
- To discuss the evolving therapeutic landscape for NSCLC patients with uncommon genetic aberrations.
Main Methods:
- Literature review focusing on recent advancements in NSCLC driver identification.
- Analysis of emerging therapeutic strategies targeting novel oncogenic drivers.
Main Results:
- Novel oncogene drivers are identified as promising therapeutic targets, expanding beyond EGFR mutations and ALK/ROS1 rearrangements.
- The therapeutic strategies for patients with these uncommon drivers are becoming more defined.
- Targeted therapies are increasingly utilized for rare and ultra-rare NSCLC patient subsets.
Conclusions:
- The identification of uncommon oncogene drivers is reshaping NSCLC diagnosis and treatment.
- Highly selective inhibitors are broadening the therapeutic armamentarium for advanced NSCLC, including rare populations.
More Related Videos
05:17Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
02:39lncRNA - Long Non-coding RNAs
02:38Mitogens and the Cell Cycle